Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.

@article{Sims2014ImplicationsOO,
  title={Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.},
  author={Natalie A Sims and Kong Wah Ng},
  journal={Current osteoporosis reports},
  year={2014},
  volume={12 1},
  pages={
          98-106
        }
}
Antiresorptive agents, used in the treatment of osteoporosis, inhibit either osteoclast formation or function. However, with these approaches, osteoblast activity is also reduced because of the loss of osteoclast-derived coupling factors that serve to stimulate bone formation. This review discusses how osteoclast inhibition influences osteoblast function, comparing the actions of an inhibitor of osteoclast formation [anti-RANKL/Denosumab (DMAB)] with that of a specific inhibitor of osteoclastic… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 104 REFERENCES

Management trends after 8 years of denosumab: follow-up after a 1-year observational phase of the phase 2 extension study

  • MR McClung, EM Lewiecki, PR Ho, MA Bolognese, B Ding, ML Geller
  • Endocr Rev. ;34:OR10–6
  • 2013

Similar Papers

Loading similar papers…